Interferon Patents (Class 424/85.4)
-
Publication number: 20130045160Abstract: The present invention relates to water soluble magnetic nanocomposite using an amphiphilic compound. Specifically, the present invention relates to water soluble magnetic nanocomposite which may be not only used as a contrast agent for magnetic resonance imaging (MRI), an intelligent contrast agent for diagnosing cancer characterized by binding a tissue-specific binder ingredient, a drug delivery system for simultaneous diagnosis and treatment by polymerizing or enveloping drugs and binding a tissue-specific binder ingredient, but also used for separating a target substance using magnetism, and a process for preparing the same.Type: ApplicationFiled: August 21, 2012Publication date: February 21, 2013Applicant: Industry-Academic Coorporation Foundation, Yonsei UniversityInventors: Seung-Joo HAM, Jin-Suck SUH, Yong-Min HUH, Ho-Geun YOON, Jae-Moon YANG
-
Patent number: 8377420Abstract: The present invention teaches a micro-porous injectable, soft elastic, fully resorbable fibrin-based composition for use as a soft tissue lumen and void filler. The composition of the present application exhibits physical characteristics, such as mechanical properties, typically seen in elastomers and mechanical stability, which is superior to fibrin alone. A variety of properties of the composition of the present invention can be effectively fine-tuned and altered by adjusting type and content of the particles as well as of the plasticizer contained in the void filler composition.Type: GrantFiled: January 11, 2011Date of Patent: February 19, 2013Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: John J. Barry, Andreas Goessl, Heinz Gulle, Monika Mangold, Melitta Bilban
-
Publication number: 20130034519Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.Type: ApplicationFiled: September 13, 2012Publication date: February 7, 2013Inventors: Trixi BRANDL, Prakash RAMAN, Pascal RIGOLLIER, Mohindra SEEPERSAUD, Oliver SIMIC
-
Publication number: 20130034522Abstract: A method of improving the pharmacokinetics of VX-222 in a patient infected with HCV comprises co-administering VX-222 and VX-950 to the patient. A method of treating a patient infected with HCV comprises administering VX-222 and VX-950 to the patient, wherein VX-222 is in an amount of about 20 mg to about 400 mg, and wherein VX-950 is in an amount of about 100 mg to about 1,500 mg. A method of treating a patient infected with HCV comprises administering a therapeutically effective amount of VX-222, wherein VX-222 is administered at an amount of about 20 mg to about 2,000 mg once a day.Type: ApplicationFiled: July 27, 2012Publication date: February 7, 2013Applicant: Vertex Pharmaceuticals IncorporatedInventors: Maria Rosario, Nathalie Chauret, Shelley George, Tara Lynn Kieffer, Margaret James Koziel, Olivier Nicolas, Louise Proulx
-
Publication number: 20130034520Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: ApplicationFiled: October 12, 2012Publication date: February 7, 2013Applicant: Bristol-Myers Squibb CompanyInventor: Bristol-Myers Squibb Company
-
Publication number: 20130034521Abstract: Provided are pyrrolo[1,2-f][1,2,4]triazinyl, imidazo[1,5-f][1,2,4]triazinyl, imidazo[1,2-f][1,2,4]triazinyl, and [1,2,4]triazolo[4,3-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.Type: ApplicationFiled: October 11, 2012Publication date: February 7, 2013Applicant: GILEAD SCIENCES, INC.Inventor: GILEAD SCIENCES, INC.
-
Patent number: 8367053Abstract: The present invention provides novel cyclosporin analogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.Type: GrantFiled: July 8, 2010Date of Patent: February 5, 2013Assignee: Enanta Pharmaceuticals, Inc.Inventors: Jiang Long, Yat Sun Or, Xuri Gao, Guoqiang Wang
-
Publication number: 20130028864Abstract: Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biochemicals from the activated mast cells, the compositions containing one or more of a flavone or flavonoid glycoside a heavily sulfated, non-bovine proteoglycan, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, a hexosamine sulfate such as D-glucosamine sulfate, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRR, a long-chain unsaturated fatty acid, a phospholipid, Krill oil, a polyamine, glutiramer acetate and interferon. Certain of the present compositions are useful in protecting against the neuropathological components of multiple sclerosis and similar inflammatory neurological diseases.Type: ApplicationFiled: September 18, 2012Publication date: January 31, 2013Applicant: Theta Biomedical Consulting & Development Co., Inc.Inventor: Theta Biomedical Consulting & Development Co.,
-
Publication number: 20130028865Abstract: The present invention relates to a combination of a macrocyclic HCV protease inhibitor, a macrocyclic non-nucleoside HCV polymerase inhibitor and a nucleoside HCV polymerase inhibitor.Type: ApplicationFiled: April 13, 2011Publication date: January 31, 2013Applicants: MEDIVIR AB, JANSSEN PHARMACEUTICALS, INC.Inventors: Tse-I Lin, Oliver Lenz, Pierre Jean-Marie Bernard Raboisson
-
Publication number: 20130028863Abstract: The present invention relates to a method for determining the redox status of a cell or tissue comprising a step consisting of determining the level of PML nuclear bodies in said cell or tissue.Type: ApplicationFiled: January 13, 2011Publication date: January 31, 2013Inventors: Hugues De The, Valerie Lallemand-Breitenbach
-
Publication number: 20130028862Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.Type: ApplicationFiled: January 20, 2012Publication date: January 31, 2013Applicant: Genentech, Inc.Inventors: Gwendolyn Fyfe, Eric Holmgren, Robert D. Mass, William Novotny
-
Publication number: 20130028859Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: ApplicationFiled: January 30, 2012Publication date: January 31, 2013Inventors: John A. Bender, Omar D. Lopez, Gan Wang, Makonen Belema, John F. Kadow
-
Patent number: 8361471Abstract: A synergistic adjuvant is provided comprising synergistically effective amounts of at least one type 1 interferon and at least one CD40 agonist, wherein these moieties may be in the same or separate compositions. In addition, fusion proteins and DNA conjugates which contain a type 1 interferon/CD40 agonist/antigen combination are provided. The use of these compositions, protein and DNA conjugates as immune adjuvants for treatment of various chronic diseases such as HIV infection and for enhancing the efficacy of vaccines (prophylactic and therapeutic) is also provided.Type: GrantFiled: July 29, 2010Date of Patent: January 29, 2013Assignee: The Regents of the University of ColoradoInventors: Ross Kedl, Phillip J. Sanchez, Catherine Haluszczak
-
Publication number: 20130022572Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.Type: ApplicationFiled: September 13, 2012Publication date: January 24, 2013Inventors: Trixi BRANDL, Prakash RAMAN, Pascal RIGOLLIER, Mohindra SEEPERSAUD, Oliver SIMIC
-
Publication number: 20130022573Abstract: Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.Type: ApplicationFiled: December 8, 2011Publication date: January 24, 2013Applicants: Selcia Limited, Gilead Sciences, Inc.Inventors: Todd Appleby, Hans G. Fliri, Andrew J. Keats, Linos Lazarides, Richard L. Mackman, Simon N. Pettit, Karine G. Poullennec, Jonathan Sanvoisin, Victoria A. Steadman, Gregory M. Watt
-
Publication number: 20130017171Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.Type: ApplicationFiled: September 20, 2012Publication date: January 17, 2013Applicants: UNIVERSITA DEGLI STUDI DI CAGLIARI, IDENIX PHARMACEUTICALS, INC.Inventors: Idenix Pharmaceuticals, Inc., Universita Degli Studi di Cagliari
-
Publication number: 20130017172Abstract: The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus and chemotherapeutic agents, and a method for preventing a neoplasm from developing drug resistance to chemotherapeutic agents. The virus is preferably a reovirus.Type: ApplicationFiled: September 24, 2012Publication date: January 17, 2013Applicant: ONCOLYTICS BIOTECH INC.Inventors: Matthew C. Coffey, Bradley G. Thompson
-
Publication number: 20130017170Abstract: Compounds represented by formula (Ia) or (Ib) and wherein R and R1 are as defined in the description, and pharmaceutically acceptable salts thereof, are disclosed; the said compounds are useful in the treatment of cell cycle proliferative disorders, e.g. cancer, associated with an altered cell cycle dependent kinase activity.Type: ApplicationFiled: September 13, 2012Publication date: January 17, 2013Applicant: NERVIANO MEDICAL SCIENCES S.R.L.Inventors: Maria Gabriella Brasca, Raffaella Amici, Daniele Fancelli, Marcella Nesi, Paolo Orsini, Fabrizio Orzi, Patrick Roussel, Anna Vulpetti, Paolo Pevarello
-
Patent number: 8349802Abstract: Methods and compositions for contributing to the treatment of cancers, especially ovarian tumors, are disclosed. The methods and compositions utilize an endothelin B agonist (ETB) to enhance the delivery and resulting efficacy of chemotherapeutic agent(s) (e.g., cisplatin and/or cyclophosphamide).Type: GrantFiled: August 29, 2011Date of Patent: January 8, 2013Assignee: Spectrum Pharmaceuticals, Inc.Inventors: Anil Gulati, Guru Reddy, Luigi Lenaz
-
Patent number: 8349312Abstract: The present invention provides novel proline substituted cyclosporinanalogue compounds, pharmaceutical compositions comprising these compounds and methods of using these compounds for the treatment of disorders and diseases, including immune disorders, inflammatory disorders and viral infections.Type: GrantFiled: July 8, 2010Date of Patent: January 8, 2013Assignee: Enanta Pharmaceuticals, Inc.Inventors: Guoqiang Wang, Yat Sun Or, Jiang Long, Xuri Gao
-
Publication number: 20130004436Abstract: Compositions and methods for treating and preventing cancer, particularly lung cancer, lymphangioleiomyomatosis and asthma are provided.Type: ApplicationFiled: September 12, 2012Publication date: January 3, 2013Inventor: Steven Lehrer
-
Publication number: 20130004415Abstract: The present invention provides peptides that home to a joint of an animal, wherein said peptide comprises an amino acid motif selected from the group consisting of NQR and ADK. Also provided are methods of treating a subject having an arthritic joint, comprising the step of administering to said subject a pharmacologically effective dose of a composition provided herein.Type: ApplicationFiled: June 29, 2012Publication date: January 3, 2013Inventors: Kamal Moudgil, Ying-hua Yang
-
Publication number: 20130004457Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: ApplicationFiled: September 11, 2012Publication date: January 3, 2013Inventors: Carol Bachand, Makonen Bekema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Gan Wang, Lawrence G. Hamann
-
Patent number: 8343477Abstract: Macrocyclic peptides are disclosed having the general formula: wherein R3, R?3, R4, R6, R?, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.Type: GrantFiled: October 25, 2007Date of Patent: January 1, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Stanley D'Andrea, Zhizhen Barbara Zheng, Paul Michael Scola
-
Publication number: 20120328565Abstract: The present invention discloses compounds of Formula I wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the treatment of HCV infection.Type: ApplicationFiled: June 21, 2012Publication date: December 27, 2012Inventors: John A. Brinkman, Andrew F. Donnell, Robert Francis Kester, Yimin Qian, Ramakanth Sarabu, Sung-Sau So
-
Publication number: 20120328564Abstract: The invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a camptothecin as a therapeutic moiety, and further relates to processes for making and using the said conjugates.Type: ApplicationFiled: August 15, 2012Publication date: December 27, 2012Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, David M. Goldenberg, Sung-Ju Moon
-
Publication number: 20120328691Abstract: The present invention relates to novel Anilinopiperazine Derivatives of Formula (I), compositions comprising the Anilinopiperazine Derivatives, and methods for using the Anilinopiperazine Derivatives for treating or preventing a proliferative disorder, cancer, an anti-proliferative disorder, inflammation, arthritis, a central nervous system disorder, a cardiovascular disease, alopecia, a neuronal disease, an ischemic injury, a viral disease, a fungal infection, or a disorder related to the activity of a protein kinase.Type: ApplicationFiled: October 29, 2007Publication date: December 27, 2012Inventors: Gerald W. Shipps, JR., Cliff C. Cheng, Xiaohua Huang, Thierry O. Fischmann, Jose S. Duca, Matthew Richards, Hongbo Zeng, Binyuan Sun, Panduranga Adulla Reddy, Tzu T. Wong, Praveen K. Tadikonda, M. Arshad Siddiqui, Marc A. Labroli, Cory Poker, Timothy J. Guzi
-
Publication number: 20120328568Abstract: The disclosure relates to uses of a purified or isolated lectin to kill bacteria, viruses, and other pathogens. In certain embodiments, the disclosure relates to method of treating or preventing an infection comprising administering a purified or isolated galectin to a subject in need thereof. In certain embodiments, the subject is at risk of, exhibiting symptoms of, or diagnosed with a pathogenic infection.Type: ApplicationFiled: February 11, 2011Publication date: December 27, 2012Applicant: EMORY UNIVERSITYInventors: Richard D Cummings, Sean R. Stowell, Connie Arthur
-
Publication number: 20120328570Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: ApplicationFiled: September 7, 2012Publication date: December 27, 2012Inventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Lawrence G. Hamann
-
Patent number: 8337826Abstract: The present invention relates to liquid formulations of human interferon-?. The formulations are characterized in that they have a buffer with a pH in the weakly acidic to neutral range of between 5 and 8, preferably between over 5.5 and 8, and that they exhibit high stability of the interferon-? in solution while retaining the molecular integrity.Type: GrantFiled: April 11, 2005Date of Patent: December 25, 2012Assignee: Rentschler Biotechnologie GmbHInventors: Michael Tschope, Thomas Siklosi, Peter Schroeder, Hans Hofer
-
Publication number: 20120321553Abstract: Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.Type: ApplicationFiled: May 1, 2012Publication date: December 20, 2012Applicant: IMMUNOMEDICS, INC.Inventors: Li Zeng, Rohini Mitra, Edmund A. Rossi, Hans J. Hansen, David M. Goldenberg
-
Patent number: 8334000Abstract: An extract of Chinese blackberry (Rubus suavissimus) has been found to inhibit angiogenesis, and two active fractions isolated. Gallic acid was shown to be one of the active anti-angiogenic compounds by an in vitro human angiogenesis model. Aqueous extracts from other plants either known or found to have gallic acid were also found to have anti-angiogenic activity. Various derivatives of gallic acid were found to inhibit angiogenesis. The extract from Chinese blackberry also slowed the growth of a pancreatic tumor and of corneal neovascularization in rats. Extracts from pomegranate were shown to inhibit angiogenesis in fat tissue. Extracts from Rubus spp, and other plants with gallic acid, and gallic acid and its derivatives will be useful for treating various diseases associated with neovascularization, including diabetic retinopathy, psoriasis, tumors, obesity, cancer, rheumatoid arthritis, etc.Type: GrantFiled: March 22, 2010Date of Patent: December 18, 2012Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical CollegeInventors: Frank L. Greenway, Zhijun Liu, Eugene A. Woltering
-
Publication number: 20120315304Abstract: The metabolization of certain phenols, monophenols or benzenediols into reactive quinone compounds, in particular ortho-quinones and related reactive intermediates, which is brought about by oxidation of monophenols and benzenediols by proteins exhibiting tyrosinase activity, such as human tyrosinase and the related proteins TRP1 and TRP2. The compounds function as haptens that become covalently bound to the tyrosinase enzymes, in particular to histidine moieties, in or near the catalytic site of proteins exhibiting tyrosinase activity, such as tyrosinase, TRP1 and TRP2. An immune response is then to be mounted against these haptenized auto-antigens to treat malignancies.Type: ApplicationFiled: June 11, 2012Publication date: December 13, 2012Applicants: ACADEMISCH ZIEKENHUIS LEIDEN, ACADEMISCH ZIEKENHUIS BIJ DE UNIVERSITEIT VAN AMSTERDAMInventors: Wiete WESTERHOF, Cornelis Joseph Maria MELIEF, Rosalie Margaretha LUITEN
-
Publication number: 20120315246Abstract: The invention is directed to novel compositions and methods for modulating inflammatory and/or immune responses. Such novel compositions are derived from extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as extraembryonic HLA-G positive or “EHP” cells) and Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells), alone or in combination with each other and/or in combination with various matrices and/or devices and/or other suitable active agents. The novel methods of modulating inflammatory and/or immune responses utilize such novel compositions.Type: ApplicationFiled: June 1, 2012Publication date: December 13, 2012Inventors: Randall G. Rupp, Richard A. Banas
-
Publication number: 20120315247Abstract: The present invention provides novel compounds useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.Type: ApplicationFiled: August 17, 2012Publication date: December 13, 2012Applicants: SUNSHINE LAKE PHARMA CO., LTD.Inventor: Ning Xi
-
Publication number: 20120308520Abstract: This invention provides crystalline recombinant interferon (rSIFN-co) having (i) the same amino acid sequence as that of human consensus interferon, and (ii) altered three-dimensional structure as compared to IFN-?2b. The interferon of the present invention exhibits enhanced biological activities. The present invention also provides a structural model of said interferon useful for drug screening and/or drug design, and mimetics of said interferon.Type: ApplicationFiled: December 16, 2010Publication date: December 6, 2012Applicant: SICHUAN HUIYANG LIFE SCIENCE & TECHNOLOGY CORP.Inventors: Guangwen Wei, Dacheng Wang
-
Publication number: 20120308519Abstract: Described herein are 4-methyl-piperazine-1-carbothioic acid amide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by hemorrhagic fever viruses, such as Arenaviruses.Type: ApplicationFiled: December 29, 2011Publication date: December 6, 2012Applicant: Siga Technologies, Inc.Inventors: Sean M. Amberg, Dongcheng Dai, Tove C. Bolken, Dennis E. Hruby
-
Publication number: 20120308517Abstract: The present invention relates to the use of compositions comprising a type III interferon and oncostatin M and to the use of said compositions for the treatment and prevention of infectious and neoplastic diseases.Type: ApplicationFiled: February 7, 2011Publication date: December 6, 2012Applicants: DIGNA BIOTECH, S.L., PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Rafael Aldabe Arregui, Iranzu Gonzalez De La Tajada, Maria Esther Larrea Leoz, Jesus Maria Prieto Valtuena
-
Patent number: 8323636Abstract: A polypeptide and polynucleotides encoding same comprising carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an IFN protein are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.Type: GrantFiled: July 28, 2011Date of Patent: December 4, 2012Assignee: Prolor Biotech Ltd.Inventors: Fuad Fares, Udi Eyal Fima
-
Publication number: 20120296403Abstract: The disclosure relates to treating muscle wasting-associated disorders in a patient, using a therapeutically effective amount of an antagonist of Fbxo40, wherein the antagonist reduces the expression, level or activity of Fbxo40. The Fbxo40 antagonist increases muscle mass, or prevents, limits or reduces muscle mass loss, in the patient. The Fbxo40 antagonist can be a low molecular weight (LMW) compound, a protein, an antibody, or an inhibitory nucleic acid, such as a siRNA. The disclosure also relates to methods of screening for antagonists of Fbxo40, and methods of diagnosing or monitoring levels of muscle mass maintenance, loss or increase.Type: ApplicationFiled: February 8, 2011Publication date: November 22, 2012Applicant: NOVARTIS AGInventors: David Glass, Jun Shi
-
Publication number: 20120294830Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.Type: ApplicationFiled: July 6, 2012Publication date: November 22, 2012Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
-
Publication number: 20120288476Abstract: Oligonucleotides bearing free, uncapped 5? phosphate group(s) are recognized by RIG-I, leading to the induction of type I IFN, IL-18 and IL-1? production. Bacterial RNA also induces type I IFN production. 5? phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. Single-stranded 5? triphosphate RNA can be used for inducing an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in a target cell-specific manner.Type: ApplicationFiled: May 8, 2012Publication date: November 15, 2012Inventors: Gunther Hartmann, Veit Hornung
-
Publication number: 20120288477Abstract: The invention relates to variants of consensus interferon protein with improved properties, such as improved anti-viral activity, and use thereof The variants are also easier to renature after denaturant treatment. The invention also relates to the preparation method of the variants consensus interferon.Type: ApplicationFiled: July 23, 2012Publication date: November 15, 2012Inventor: Lin Wang
-
Publication number: 20120282221Abstract: This invention relates to a bromo-phenyl substituted thiazolyl dihydropyrimidine, its preparation method and use as a medicament for treating and preventing hepatitis B infections. The invention also relates to a composition comprising the dihydropyrimidine, one or more antiviral agents and, optionally, an immunomodulator for treating and preventing HBV infections.Type: ApplicationFiled: July 17, 2012Publication date: November 8, 2012Applicant: SUNSHINE LAKE PHARMA CO., LTD.Inventors: Goldmann SIEGFRIED, Jing LI, Yi Song LIU
-
Publication number: 20120282219Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.Type: ApplicationFiled: July 3, 2012Publication date: November 8, 2012Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: ROBERT EDWARD BABINE, SHU HUI CHEN, IVAN COLLADO, CRISTINA GARCIA-PAREDES, JOHN IRVIN GLASS, DEQI GUO, LING JIN, JASON ERIC LAMAR, RAYMOND SAMUEL PARKER, III, NANCY JUNE SNYDER, XICHENG DAVID SUN, MARK JOSEPH TEBBE, FRANTZ VICTOR, Q. MAY WANG, YVONNE YEE MAI YIP, ROBERT B. PERNI, LUC FARMER
-
Patent number: 8303944Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: GrantFiled: February 13, 2008Date of Patent: November 6, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Gan Wang, Lawrence G. Hamann
-
Publication number: 20120276047Abstract: The present invention relates to novel fused tricyclic compounds, compositions comprising at least one fused tricyclic compound, and methods of using fused tricyclic compounds for treating or preventing a viral infection or a virus-related disorder in a patient.Type: ApplicationFiled: November 23, 2010Publication date: November 1, 2012Inventors: Stuart B. Rosenblum, Kevin X. Chen, Joseph A. Kozlowski, F. George Njoroge
-
Publication number: 20120276048Abstract: Methods for extended treatment of multiple sclerosis are described.Type: ApplicationFiled: July 5, 2012Publication date: November 1, 2012Inventors: Michael Panzara, Martin Toal, Frances Lynn
-
Publication number: 20120276049Abstract: Compositions that are fusion proteins of antibodies to dendritic cell receptors, exemplified by anti-DEC205 and anti-33D1 antibodies, to peptide sequences that are immunosuppressive or tolerogenic are provided for treatment of autoimmune diseases such as multiple sclerosis. Also provided are pharmaceutical compositions including the fusion proteins, as well as therapeutic methods for administering the fusion proteins.Type: ApplicationFiled: April 9, 2012Publication date: November 1, 2012Applicant: President and Fellows of Harvard CollegeInventors: Joel N. H. Stern, Jack L. Strominger
-
Patent number: 8298525Abstract: Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments the autoimmune disease is multiple sclerosis. In certain embodiments administration of interferon-beta is combined with administration of an antagonist of the IL-2R to provide significant clinical improvement in a subject with an autoimmune disease.Type: GrantFiled: March 10, 2009Date of Patent: October 30, 2012Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Roland Martin, Henry McFarland, Bibiana Bielekova, Thomas Waldmann